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Introduction
Chronic obstructive pulmonary disease (COPD) is
one of the principal causes of death in most coun-
tries and its prevalence is increasing. It is a multi-
component disease characterised by airﬂow limita-
tion in the lungs that is generally progressive and
not fully reversible (1). While the presence and sever-
ity of symptoms can follow a variable course, charac-
teristic symptoms include chronic cough, sputum
production and progressive dyspnoea (1). Acute
exacerbations, characterised by physiological deterio-
ration and an increase in airway inﬂammation, are
common, particularly in the later stages of the dis-
ease, and have a considerable impact on quality of
life, daily activities and general well-being (1–4).
Acute exacerbations, in particular, are indicators of a
poor prognosis, with mortality risk increasing with
the frequency of severe exacerbations (5). Evidence
suggests that COPD may be variable throughout the
day, with symptoms and activity limitation being
most problematic in the mornings (6). In patients
with severe COPD, shortness of breath is reported to
be the most frequently reported symptom, impacting
greatly on morning routines and daily life (7).
Currently, there are several recommended classes
of therapy for COPD, of which bronchodilators
(including b2-agonists and anticholinergics) are the
mainstay of symptom management in mild and
moderate disease, prescribed on an as-needed basis
for mild COPD and as a maintenance therapy for
moderate COPD (1). For the treatment of more
severe COPD, guidelines recommend the addition
of inhaled corticosteroids (ICSs) to long-acting
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1136 doi: 10.1111/j.1742-1241.2009.02139.xbronchodilator therapy (1). Combinations of thera-
pies have been investigated with a view to their
complementary modes of action enabling multiple
components of the disease to be addressed. Data
from recent clinical trials indicate that triple therapy,
combining an anticholinergic with an ICS and a
long-acting b2-agonist (LABA), may provide clinical
beneﬁts additional to those associated with each
treatment alone in patients with moderate to severe
COPD (8–11). This article reviews the evidence for
treatment strategies used in COPD with a focus on
combination therapies.
Guidelines for COPD management
The objectives of COPD management, as deﬁned by
the Global Initiative for Chronic Obstructive Lung
Disease (GOLD) guidelines, are to relieve symptoms,
prevent disease progression, improve exercise toler-
ance and health status, prevent and treat complica-
tions and exacerbations and reduce mortality (1).
The poor prognosis and mortality associated with
exacerbations of COPD mean that reducing the fre-
quency and severity of exacerbations is one of the
central components of a management plan.
As COPD is a progressive disease, guidelines
including those of GOLD (1), the American Thoracic
Society⁄European Respiratory Society (12) and the
National Institute for Health and Clinical Excellence
(13) recommend a stepwise approach to treatment
(Figure 1). Stages of severity are deﬁned according to
symptoms and lung function and therapy is tailored
to the individual according to their disease stage and
treatment response. Bronchodilators are central to
the symptomatic management of COPD. Their abil-
ity to relax smooth muscle cells in the airway allows
improved airﬂow, indicated by improvements in spi-
rometric parameters and reduced breathlessness
(1,14). While bronchodilators do not modify the
decline of lung function in COPD, evidence does
suggest they can reduce the rate of exacerbations
compared with placebo (15,16) and improve dysp-
noea, quality of life and exercise capacity (17–19). In
the early stages of COPD (mild; stage I), short-acting
inhaled bronchodilators are the recommended ﬁrst-
line therapy, to be used on an as-needed basis for
rapid control of symptoms. These agents have a fast
onset of action but require multiple daily dosing,
with the choice of agent depending on availability
and on the patient’s response in terms of symptom
relief and side effects. Short-acting b2-agonists have a
bronchodilatory effect that lasts for 4–6 h, while
short-acting anticholinergics last up to 9 h (1). For
patients with moderate (stage II) to very severe
(stage IV) COPD whose dyspnoea is not controlled
with short-acting bronchodilators, adding regular
maintenance treatment with long-acting inhaled
bronchodilators is recommended. The short-acting
bronchodilator may still be used as needed if
required. Long-acting bronchodilators, including
LABAs such as formoterol or salmeterol, and long-
acting anticholinergics such as tiotropium can be
more effective than short-acting agents and provide
sustained improvements (20–22). Slow-release prepa-
rations of theophylline have efﬁcacy in COPD and
may possess an anti-inﬂammatory effect (23,24), but
Figure 1 Therapy at each stage of chronic obstructive pulmonary disease (COPD), as recommended by Global Initiative
for Chronic Obstructive Lung Disease (GOLD) guidelines (1)
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that of LABAs (25) and the agent is associated with
potential toxicities. Consequently, theophylline is
only recommended when inhaled bronchodilators are
not available (1). When symptoms are not controlled
by one class of bronchodilator, combination treat-
ment with the alternative class is recommended and
may improve efﬁcacy and decrease the risk of side
effects (1). For patients with COPD stages III–IV and
a history of repeated exacerbations, guidelines rec-
ommend adding an ICS to long-acting bronchodila-
tor therapy (1). Two ICS⁄LABA combinations have
received regulatory approval for COPD: budesonide⁄
formoterol (Symbicort
 ; AstraZeneca, Lund,
Sweden) and salmeterol⁄ﬂuticasone (Seretide ;
GlaxoSmithKline, Greenford, UK).
Evidence supporting use of
long-acting bronchodilators in COPD
Long-acting anticholinergics
Anticholinergics act by blocking the effect of acetyl-
choline on muscarinic receptors (Figure 2). The
long-acting inhaled anticholinergic tiotropium is one
of the most widely prescribed agents for COPD and
is recommended as maintenance therapy for patients
with COPD of at least moderate severity. Tiotropium
disassociates slowly from the M1 and M3 muscarinic
receptors, providing bronchodilation for more than
24 h and thus making it suitable for once-daily
administration (26). Evidence supports signiﬁcant
improvements in bronchodilation and lung function
vs. placebo with once-daily dosing that are sustained
for 24 h according to measurements of trough forced
expiratory volume in 1 s (FEV1) 1 h predose, vital
capacity and inspiratory capacity (27–30). However,
the recent Understanding the Potential Long-term
Impacts on Function with Tiotropium (UPLIFT)
study – a randomised, double-blind trial comparing
4 years of therapy with either tiotropium or placebo
in almost 6000 patients – showed that mean
improvements in FEV1 with tiotropium (ranging 87–
103 ml before bronchodilation and 47–65 ml after
bronchodilation) were signiﬁcantly better than pla-
cebo at all time points after randomisation
(p < 0.001), although the differences in mean decline
in FEV1 were not statistically signiﬁcant (8). The
authors suggest this ﬁnding may be related to the
protocol permitting patients to continue using previ-
ously prescribed medications other than inhaled anti-
cholinergics, e.g. ICS and LABA, with the high rate
of prescriptions for concomitant respiratory medica-
tions in both arms of the study (Table 1; 8).
Anticholinergic agents are poorly absorbed system-
ically, which limits systemic adverse effects. The most
frequent side effect reported in clinical trials is dry-
ness of the mouth and more serious effects appear to
be rare (31). There are recent reports of elevations in
cardiovascular risk, although these ﬁndings have not
been fully elucidated and this risk remains uncertain.
While a retrospective database analysis showed an
increased risk of mortality with the inhaled
anticholinergic ipratropium [odds ratio 1.34; 95%
conﬁdence interval (CI): 1.22–1.47] (32) and a meta-
analysis of ﬁve long-term trials involving more than
7000 patients found an elevated risk of cardiovascu-
lar events and death with both ipratropium [relative
risk (RR) 1.57, 95% CI: 1.08–2.28; p = 0.02 vs. con-
trol] and tiotropium (RR 2.12, 95% CI: 1.22–3.67;
p = 0.008 vs. control) (33), long-term results from
the 4-year UPLIFT study did not conﬁrm any
Figure 2 Mechanisms of action of bronchodilators on
airway smooth muscle (14). AMP, adenoside
monophosphate; cAMP, cyclic adenosine monophosphate;
M1,M 2 and M3 are muscarinic receptors. Reprinted from
Ref. (14). Copyright
ª (2007)
Table 1 Respiratory medications used at baseline in
UPLIFT (8)
Medication use (%)
Tiotropium
(n = 2986)
Placebo
(n = 3006)
Any 93.4 93.1
Inhaled anticholinergic*
Short-acting 44.9 44.1
Long-acting 2.0 1.6
Inhaled b2-agonist*
Short-acting 68.5 68.1
Long-acting 60.1 60.1
Corticosteroid
Inhaled* 61.6 61.9
Oral 8.4 8.3
Theophylline compound 28.4 28.5
Mucolytic agent 7.4 6.9
Leucotriene-receptor antagonist 3.3 3.1
Supplemental oxygen 2.3 1.9
*This medication was used either alone or as a ﬁxed
combination. UPLIFT, Understanding the Potential Long-term
Impacts on Function with Tiotropium.
1138 Optimising treatment for COPD
ª 2009 The Author
Journal compilation ª 2009 Blackwell Publishing Ltd Int J Clin Pract, August 2009, 63, 8, 1136–1149increased risk with tiotropium. In UPLIFT, the risk
of death, cardiovascular death, myocardial infarction
or stroke was not signiﬁcantly increased vs. placebo;
on the contrary, examination of all serious cardiac
and lower respiratory tract adverse events indicated
that tiotropium reduced the risk of serious adverse
events (8).
Long-acting b2-agonists
Long-acting b2-agonists, such as salmeterol and for-
moterol, induce bronchodilation by acting on the
b2-adrenergic receptors located in the smooth muscle
of the airways (Figure 2; 14,34). LABAs have a greater
duration of effect than short-acting bronchodilators
(more than 12 h vs. 4–6 h), with no loss of effect
with long-term use (20,21,35). For example, studies
of formoterol report prolonged and rapid bronchodi-
lation with an onset of action at around 5 min,
which is comparable with salbutamol and faster than
salmeterol and which reaches peak bronchodilation
within 1 h (21,36–39). The variations in speed of
action between the agents may be because of the dif-
ferences in mode of action; whereas salmeterol acts
as a partial agonist of the b2-adrenergic receptor, for-
moterol is a full agonist (40). Evidence suggests that
LABA monotherapy also results in greater improve-
ment of symptoms, fewer exacerbations, reduced res-
cue use and improved overall health status compared
with short-acting bronchodilator therapy (20,21,41).
In a randomised controlled trial comparing
12 weeks’ administration of formoterol and the short-
acting anticholinergic ipratropium, formoterol signiﬁ-
cantly increased the area under the curve for FEV1
compared with ipratropium (p < 0.025) (20). Formo-
terol also signiﬁcantly improved all symptoms (all
p £ 0.007) and quality of life, as assessed using the St
George’s Respiratory Questionnaire (SGRQ) (p < 0.01
for total scores), and reduced the proportion of ‘bad
days’ (deﬁned as days with at least two individual
symptom scores of two or more and⁄or a reduction in
peak expiratory ﬂow from baseline of more than 20%;
p £ 0.001) and use of rescue medication (p < 0.001)
compared with placebo, whereas ipratropium did not
show a signiﬁcant effect (20).
Inhaled LABA monotherapies are generally well
tolerated and adverse events tend to be dose related
(1,42). The increased risk of asthma mortality
observed in the large Salmeterol Multicentre Asthma
Research Trial has not been paralleled by an observed
increased risk of COPD mortality in COPD trials
involving LABAs. Rather, the Towards a Revolution
in COPD Health (TORCH) study, which compared
salmeterol⁄ﬂuticasone with placebo, salmeterol alone
or ﬂuticasone alone, reported numerical reductions
in mortality in both salmeterol arms compared with
the placebo and ICS arms, although these reductions
did not reach statistical signiﬁcance (43). Unlike ear-
lier large randomised controlled trials, which included
only patients with GOLD stage III–IV COPD, TORCH
included patients with mild airﬂow obstruction
(equivalent to GOLD stage II). In the last few years,
many large studies have included stage II COPD
patients, although the percentage of subjects included
at each level of severity (stages II–IV) has varied
between studies.
Use of LABAs and long-acting anticholinergics
in combination
Given the different mechanisms and durations of
action of LABAs and long-acting anticholinergics,
combining agents from these two classes of long-act-
ing bronchodilator may have the potential to provide
better bronchodilation than the individual agents.
Indeed, a number of randomised studies have
reported complementary effects in trials using com-
bination treatment with a LABA and tiotropium.
Cazzola et al. reported that formoterol in combina-
tion with tiotropium elicited a signiﬁcantly faster
onset of action than tiotropium alone (but not for-
moterol alone) according to change in FEV1 10 min
after inhalation (p = 0.016) and showed a trend for
greater maximum bronchodilation according to mea-
sures of FEV1 performed over 24 h (44). Similar
effects were subsequently shown for salmeterol in
combination with tiotropium (45). Addition of for-
moterol to tiotropium has also been shown to signif-
icantly reduce the use of rescue medications
compared with tiotropium or formoterol alone and
to be well tolerated (46,47). Recent data suggest such
a combination may offer beneﬁts for lung function
that are greater than those with salmeterol plus an
ICS. A 6-week, multi-centre, randomised, double-
blind study compared formoterol plus tiotropium
with salmeterol plus ﬂuticasone in more than 600
patients with moderate COPD (48). Formoterol plus
tiotropium produced signiﬁcantly greater improve-
ments in 12-h lung function proﬁles, indicated by
the area under the curve for FEV1 (mean difference
78 ml, p = 0.0006) and forced vital capacity (FVC)
(mean difference 173 ml, p = 0.0001), compared
with salmeterol plus ﬂuticasone. These data suggest
that further studies investigating the beneﬁts of com-
bining tiotropium and LABAs are warranted.
Can addition of ICS improve patient
outcomes?
Inhaled corticosteroids exert a range of effects in the
airways that suggest their utility in COPD (49).
However, unlike the large body of evidence and
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as the mainstay of therapy in COPD, there are con-
ﬂicting results as to the beneﬁts of ICS therapy in
COPD. A number of large randomised controlled
trials have suggested that ICS monotherapy may
not modify the natural history of COPD (50–52).
While some small improvements in FEV1 have been
reported, ICS monotherapy appears to have no
signiﬁcant effect on long-term decline in FEV1
in patients with mild to moderately severe COPD.
However, data from a wide range of studies, meta-
analyses and reviews have shown that ICS decreases
the risk of exacerbations, slows the rate of decline of
health-related quality of life and tends to improve
survival (50–60). In particular, the Inhaled Steroids
in Obstructive Lung Disease study, a UK trial in
more than 700 people with moderate-to-severe
COPD, reported a 25% decrease in acute exacerba-
tions with ﬂuticasone vs. placebo (p = 0.026; 52)
that was shown to be independently associated with
prevention of deterioration in health status according
to SGRQ (61). Theoretically, a favourable impact of
ICS on outcomes in COPD could arise from modiﬁ-
cation of the inﬂammatory response, but it could
also occur via effects in upregulating the b2-adrener-
gic receptor (62), thus maximising the effect of
b2-agonists.
As a result of these ﬁndings and the continual
emergence of clinical data showing the beneﬁts of
combining ICS with LABA (discussed below), guide-
lines recommend ICS for regular treatment in com-
bination with a long-acting bronchodilator for
patients with severe COPD (FEV1 < 50% predicted)
and repeated acute exacerbations requiring treatment
with antibiotics or oral corticosteroids (Figure 1;
1,12). The reported synergistic action of ICS com-
bined with b2-agonists may yet support early utilisa-
tion of ICS in mild or moderate COPD. The results
of TORCH and UPLIFT, which included patients
with moderate (stage II) COPD (46% of the popula-
tion in UPLIFT), appear to support hypothetical
beneﬁts of ICS in milder COPD (8,43). Unpublished
subgroup analyses of patients with moderate COPD
in these two studies have suggested an effect on exac-
erbation rate and other outcome parameters (per-
sonal communication). However, further work is
necessary to provide additional detail on the mode
of action and the clinical effects, if any, of ICS in
mild and moderate COPD.
Short-term side effects reported with ICS mono-
therapy include oral candidiasis and hoarseness
(55,63). More serious adverse events are rare,
although long-term effects do require further investi-
gation. The impact of long-term ICS therapy on
bone mineral density has been difﬁcult to evaluate
because of confounding factors, but recent studies
suggest no association with an increased risk of bone
mineral density or fracture (64,65). An increased
incidence of pneumonia has been observed in some
clinical studies using ICS therapy, either as mono-
therapy or in combination with a LABA (43,66–68).
This ﬁnding has raised some concerns but whether
this relationship applies to all ICS therapies remains
uncertain as most of the data are heavily inﬂuenced
by ﬂuticasone and further investigation is required.
Long-acting anticholinergics plus ICS
Very few studies published to date have been
designed speciﬁcally to evaluate the effect of ICS and
tiotropium combinations on clinical outcomes and
this is an area that warrants future study. One study
in Korea randomised 100 patients with COPD to
receive tiotropium with or without the addition of
low-dose budesonide for 6 weeks (69). While
changes in trough FEV1 and the use of rescue medi-
cation were similar between the two groups, the tiot-
ropium⁄budesonide combination was associated with
a signiﬁcant improvement in health status according
to SGRQ total score (p = 0.003). In a second recent
Korean study, Choi et al. (70) reported improve-
ments in dyspnoea and lung function over 6 months
of treatment with tiotropium and ICS combination
therapy in patients with COPD and chronic obstruc-
tive bronchial asthma as well as a reduction in the
frequency of exacerbations.
ICS⁄LABA
Combination therapy with an ICS and a LABA is rec-
ommended and widely used for patients with more
severe COPD. The value of this combination and its
potential to address multiple components of the dis-
ease has been established in large clinical trials. In par-
ticular, several studies have shown that treatment with
the ICS⁄LABA combination therapies budesonide⁄
formoterol or salmeterol⁄ﬂuticasone improve lung
function and exacerbations compared with placebo or
LABA alone (Table 2; 15,16,43,71). One pivotal study
demonstrating long-term improvements in lung func-
tion was carried out by Calverley et al. (71) who
randomised more than 1000 people to receive budeso-
nide⁄formoterol, budesonide alone, formoterol alone
or placebo for 12 months. Initial improvements in
FEV1 were maintained throughout the study with
budesonide⁄formoterol, while, in contrast, FEV1
declined greatly and rapidly with all other treatments.
The difference in percentage decline from baseline was
signiﬁcant with budesonide⁄formoterol compared
with placebo (14%), budesonide (11%) and formoter-
ol (5%) (p < 0.005). Calverley et al. (71) also reported
a prolonged time to ﬁrst exacerbation with
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ments (all p < 0.05). Studies have also documented
clinically meaningful improvements in health status
with ICS⁄LABA therapy (16,71,72) and clinically
meaningful improvements in patients’ health-related
quality of life with budesonide⁄formoterol therapy,
according to the SGRQ (71). Budesonide⁄formoterol
provided a sustained reduction in SGRQ score,
which after 12 months of treatment was reduced
by 7.5 compared with placebo (p < 0.001); a
reduction in score of 4 is considered a clinically
relevant improvement (Figure 3). The improvement
was also superior to that seen with formoterol and
budesonide alone.
Notably, emerging data have supported an anti-
inﬂammatory effect of budesonide⁄formoterol during
exacerbations of COPD. In a small double-blind
study comparing 14-day treatment with budeso-
nide⁄formoterol or placebo in patients experiencing
a mild to moderate COPD exacerbation, sputum
eosinophils were signiﬁcantly reduced by budeso-
nide⁄formoterol ()57%) but increased with placebo
(+24%) (p = 0.01; 73). Total symptom scores also
improved compared with placebo (p = 0.01).
Evidence suggests that ICS⁄LABA combinations
may have the potential to reduce mortality in COPD
(Figure 4; 43,66,72). However, the large 3-year,
randomised, double-blind, global mortality study
TORCH (in patients with GOLD stage II–III COPD),
did not demonstrate a signiﬁcant beneﬁt with regard
to mortality (43). A trend towards reduced all-cause
mortality (the primary end-point) of 17.5% was
reported with salmeterol⁄ﬂuticasone vs. placebo
(p = 0.052; Figure 4B). The monotherapies (salme-
terol and ﬂuticasone) had no impact on survival.
The lack of signiﬁcant effect with the combination
may have been related to an underpowering of the
study arising from fewer deaths than anticipated in
the placebo arm and a higher rate of dropout in the
placebo arm. A post hoc analysis of the TORCH
study indicated that the ICS⁄LABA combination had
slowed the progression of COPD in this patient pop-
ulation (74). Compared with placebo, salmeterol⁄ﬂu-
ticasone reduced the rate of decline of FEV1 by
16 ml⁄year (p < 0.001) – a greater difference than
observed with the individual agents. A reduction in
mortality has also been reported with budeso-
nide⁄formoterol: retrospective pooled data from two
large 1-year studies revealed that budesonide, either
alone or in combination with formoterol, signiﬁ-
cantly reduced the risk of death from any cause com-
pared with formoterol or placebo maintenance
therapy (Figure 4A; 72). The ﬁnding that combina-
tion ICS⁄LABA therapy may have a greater effect on
mortality than the individual agents alone is sup-
ported by retrospective data (75,76). These include a
retrospective analysis of the UK General Practice
Research Database that looked at prognosis in the
year after a ﬁrst hospitalisation for COPD (75). The
combined risk of rehospitalisation or death was sig-
niﬁcantly reduced by 41% in users of combined
ICS⁄LABA therapy compared with a control group
using short-acting bronchodilators only, but was only
16% in those prescribed ICS alone and 10% with
Figure 3 Improvements in health-related quality of life with budesonide⁄formoterol (71). Time course of the change in
St George’s Respiratory Questionnaire (SGRQ) total scores relative to ﬁrst attendance at clinic visits, in patients with
moderate severe COPD. Treatment with budesonide⁄formoterol and the individual monotherapies improved (reduced)
SGRQ total scores vs. placebo, with the greatest improvement occurring with budesonide⁄formoterol. Differences at
12 months were )7.5 (p < 0.001), )3.0 (p < 0.05) and )4.1 (p < 0.01) vs. placebo for budesonide⁄formoterol, budesonide
alone and formoterol alone respectively. Reprinted from Ref. (71). Copyright ª (2003), with permission from European
Respiratory Society Journals
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Journal compilation ª 2009 Blackwell Publishing Ltd Int J Clin Pract, August 2009, 63, 8, 1136–1149Figure 4 Kaplan–Meier curves for mortality. Kaplan–Meier curves for mortality for budesonide-containing therapies
(budesonide alone or budesonide⁄formoterol) vs. (A) reference (non-budesonide) groups (72), (B) salmeterol⁄ﬂuticasone
vs. placebo (43) and (C) salmeterol⁄ﬂuticasone (SFC) vs. tiotropium (66). (A) Reprinted from Ref. (72). Copyright ª
(2008), with permission from Respiratory Medicine. (B) Reprinted from the Ref. (43). Copyright ª (2007) Massachusetts
Medical Society. All rights reserved. (C) Reprinted from Ref. (66). Ofﬁcial Journal of the American Thoracic Society ª
American Thoracic Society
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observational study reported a 22% reduction in the
risk for cardiovascular death, combined cardiovascu-
lar and respiratory death and all-cause mortality in
patients exposed to ICS⁄LABA (32).
Data also suggest that mortality may be lower with
ICS⁄LABA compared with tiotropium alone – a signif-
icant ﬁnding given the unclear risks of mortality with
tiotropium alone. The large, 2-year Investigating New
Standards for Prophylaxis in Reduction of Exacerba-
tions (INSPIRE) study was the ﬁrst study to compare
an ICS⁄LABA combination (salmeterol⁄ﬂuticasone)
with a long-acting bronchodilator (tiotropium) head-
to-head in severe to very severe COPD (66). The study
revealed a signiﬁcant 3% absolute reduction in mortal-
ity with salmeterol⁄ﬂuticasone compared with tiotro-
pium alone (p = 0.032; Figure 4C) despite not being
powered for mortality. The primary end-point, the
overall rate of exacerbations, was not signiﬁcantly dif-
ferent between the two treatment arms. While exacer-
bations requiring oral corticosteroids were less
frequent with salmeterol⁄ﬂuticasone vs. tiotropium
(p = 0.039), exacerbations requiring antibiotics
and hospitalisations were more frequent with
salmeterol⁄ﬂuticasone vs. tiotropium (p = 0.028 and
p = 0.085 respectively). The same study reported a
signiﬁcantly lower SGRQ total score with salmeterol⁄
ﬂuticasone than with tiotropium ()2.1 units, 95% CI:
)4.0 to )0.1; p = 0.038), but this did not reach the
minimal clinically important difference of four units.
It is important to bear in mind a number of impor-
tant limitations in the INSPIRE study, including a
signiﬁcantly higher drop-out rate in the tiotropium
arm (p = 0.005). To date, budesonide⁄formoterol has
not been directly compared with tiotropium in
COPD.
ICS⁄LABA in addition to tiotropium
The efﬁcacy of combining tiotropium with an
ICS⁄LABA is of increasing interest given that LABAs
and long-acting anticholinergics have distinct yet com-
plementary mechanisms of action (Figure 2). The
effect of combining tiotropium with other COPD
medications has already been the subject of a number
of studies (Table 3; 8,10,11,77). For example, in a large
veterans administration trial, the addition of tiotropi-
um to other COPD medications reduced the rate of
exacerbations by 19% (p = 0.031) vs. placebo in
patients with moderate to severe COPD and showed a
non-signiﬁcant reduction in COPD-related hospitali-
sations (77). However, the study period was relatively
short and the beneﬁcial effects were modest. The
4-year UPLIFT trial provided additional support for
these trends. In this study, which enrolled patients
with moderate to very severe COPD (> 40% had stage
II COPD), tiotropium used with any prescribed
COPD medication other than another inhaled anti-
cholinergic signiﬁcantly improved health-related
quality of life, rate of exacerbations and lung function
vs. placebo (Figure 5; 8). However, the rate of decline
in FEV1 (primary end-point) did not improve. There
were a number of limitations to UPLIFT. As discussed
earlier, concomitant therapies could include other
Table 3 Summary of results from recent studies on ICS⁄LABA + tiotropium combinations
References
Study
size (N) Study duration
COPD
severity
ICS⁄LABA + TIO (or any medication) vs. comparator at study end
FEV1
Severe
exacerbations
(% reduction)
Symptom
control
Any COPD medication + tiotropium (18 lg once daily) vs. PBO
Niewoehner et al. (77) 1829 (99% men) 6 month Moderate
to severe
Increase in FEV1 )19% vs. PBO* –
Tashkin et al. (8) 5993 4 years Moderate
to severe
Rate of
decline: ns
)14%
Leading to
hospitalisation
SGRQ total score
+2.7
ICS⁄LABA (salmeterol⁄ﬂuticasone or budesonide⁄formoterol) + tiotropium vs. ICS⁄LABA
Perng et al. (11) 46 1 month with TIO Severe Increase in FEV1 – SGRQ total score
+6.5
Salmeterol⁄ﬂuticasone + tiotropium vs. tiotropium + PBO
Aaron et al. (10) 449 1 year Moderate
to severe
+0.027 vs.
TIO + PBO*
)2.8% vs. TIO
+ PBO (ns)
SGRQ total score
+4.1 vs. TIO + PBO*
*p < 0.05; p < 0.01; p < 0.001. COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; ICS, inhaled corticosteroid; LABA, long-act-
ing b2-agonist; ns, non-signiﬁcant; PBO, placebo; TIO, tiotropium; SGRQ, St George’s respiratory questionnaire.
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(Table 1). In addition, there was a higher rate of
discontinuation in the placebo group (44.6% vs.
36.2%; p < 0.001) and these patients had a greater rate
of decline in postbronchodilator FEV1 compared with
those who completed the study. Thus, those in the
placebo group who completed the study may represent
‘healthy survivors’.
While the aforementioned studies combined tiot-
ropium with any other concomitant COPD medica-
tion (apart from anticholinergics) further studies
have more speciﬁcally reported that triple therapy
with tiotropium combined with an ICS⁄LABA com-
bination provides clinical beneﬁts in lung function
and improved quality of life. Perng et al. (11)
showed that in patients with severe COPD treated
with ICS⁄LABA therapy (57% of patients with
salmeterol⁄ﬂuticasone, 43% with budesonide⁄formo-
terol), adding tiotropium for 1 month signiﬁcantly
improved lung function according to FVC, FEV1 and
inspiratory capacity. After tiotropium withdrawal,
FVC, FEV1 and inspiratory capacity decreased mark-
edly. Addition of tiotropium also led to signiﬁcant
improvements in SGRQ total scores (p < 0.001).
These ﬁndings are supported by data published by
Aaron et al. (10) which showed that, after 1 year,
salmeterol⁄ﬂuticasone plus tiotropium improved
lung function (p = 0.049), quality of life (improve-
ment in SGRQ > 4 points vs. tiotropium alone;
p = 0.01) and hospitalisation rates for exacerbations
(95% CI: 0.33–0.86) compared with tiotropium
alone in patients with moderate to severe COPD.
By contrast, similar signiﬁcant beneﬁts with regard
to hospitalisation rates were not seen for ther-
apy with tiotropium plus salmeterol. In this
study, the combination salmeterol⁄ﬂuticasone and
tiotropium compared with tiotropium alone had no
signiﬁcant effect on the rate of exacerbations,
although this effect may have arisen through
underpowering of the study and the small number
of exacerbations that occurred. It is clear that, while
the potential appears substantial, more research is
needed into the speciﬁc effects of adding tiotropium
to ICS⁄LABA.
Figure 5 Clinical beneﬁts of adding tiotropium to other respiratory medications (8). (A) Probability of treatment
discontinuation, (B) mean forced expiratory volume in 1 s (FEV1) and (C) forced vital capacity (FVC) before and after
bronchodilation and (D) scores for health-related quality of life in patients randomised to receive tiotropium (18 lg once
daily) plus any other COPD medication apart from anticholinergics vs. placebo. Bars represent standard errors and
horizontal dashed lines represent baseline levels. *p < 0.001; p = 0.002; p = 0.04. Reprinted from Ref. (8). Copyright ª
(2008) Massachusetts Medical Society. All rights reserved.
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COPD
Speciﬁc non-pharmacological strategies assume an
important role in management of advanced COPD.
Oxygen therapy is one of the principal non-pharma-
cological treatments for patients with very severe
(stage IV), hypoxic COPD (1) and has been shown
to improve survival (78). The beneﬁts of intermittent
non-invasive ventilation in patients with hypercapnic
respiratory failure are less clear (79), and a multi-
centre study is underway in Germany with the aim
of providing new data. Controlled data on pharma-
cological interventions are generally not available for
patients with respiratory failure. However, as exacer-
bation rate is the key prognostic factor in these
patients, it may be argued that any pharmacological
therapy with evidence to support reductions in exac-
erbations continues to play a role in optimised man-
agement.
Investigating budesonide⁄formoterol
added to tiotropium: the CLIMB study
As yet, no study has speciﬁcally reported the treatment
beneﬁts of triple therapy combining tiotropium with
budesonide⁄formoterol in patients with COPD. To
meet this need, the 3-month CLIMB study (Evaluation
of Efﬁcacy and Safety of Symbicort as an Add-on
Treatment to Spiriva in Patients With Severe COPD)
was initiated in May 2007 (ClinicalTrials.gov Identi-
ﬁer: NCT00496470; http://clinicaltrials.gov/ct2/show/
NCT00496470). CLIMB has enrolled 990 patients from
nine countries with GOLD stage II–IV COPD (Figure
6). Patients are aged ‡ 40 years, have had a clinical
diagnosis of COPD with symptoms for at least
2 years and experienced at least one COPD exacerba-
tion in the previous 12 months, are current or previ-
ous smokers with a smoking history of ‡ 10 pack
years and have an FEV1 £ 50% of predicted normal
value and FEV1⁄FVC < 70% prebronchodilator. The
primary efﬁcacy outcome measure is the change in
predose FEV1 from baseline, as assessed using spi-
rometry at clinic visits. Other important variables
assessed include time to ﬁrst exacerbation and
frequency of exacerbations, health-related quality of
life according to SGRQ and morning symptoms and
activities. Any effect of budesonide⁄formoterol added
to tiotropium on improving morning activities
and morning lung function will be notable in light
of evidence suggesting COPD patients struggle to
undertake morning activities (6).
A number of design features in CLIMB may elimi-
nate some of the limitations affecting the previous
studies of triple therapy involving ICS⁄LABA and
tiotropium. Notably, the CLIMB protocol does not
permit the addition of concomitant maintenance
therapies, whereas studies such as UPLIFT have
allowed concomitant therapy other than anticholin-
ergics, thus potentially confounding results. In addi-
tion, CLIMB includes a phase withdrawal during the
run-in period which allows patients who used ICS
before the study to withdraw before randomisation if
dissatisﬁed with the management of their symptoms
with tiotropium alone. This, together with the use of
active symptomatic treatment (all patients receive
tiotropium after study enrolment), should overcome
differential dropout which can modify the study out-
come. Differential dropout from a study favours the
less effective treatment, resulting in a ‘healthy survi-
vor effect’, particularly in placebo-treated patients
who receive no symptomatic treatment, reducing the
Figure 6 CLIMB study design. ICS, inhaled corticosteroid; LABA, long-acting b2-agonist. *All doses expressed as metered
doses
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this has been a limitation of some of the previous
studies discussed (8,10). The ﬁrst results from
CLIMB are expected to report in mid-2009.
Conclusions
Chronic obstructive pulmonary disease is a multi-
component disease; for optimal treatment, combin-
ing therapies with complementary modes of action
enables multiple components of the disease to be
treated. Current guidelines recommend ICS⁄LABA
combination therapy for the management of severe
COPD and several randomised clinical trials have
shown the beneﬁts of this approach. However, recent
evidence suggests that triple therapy combining
ICS⁄LABA with tiotropium can provide further clini-
cal beneﬁts and may improve quality of life because
of the effects of their complementary modes of
action in maintaining airway calibre. Further clinical
evidence is required to conﬁrm the extent of these
beneﬁts, particularly in the morning when the impact
of the disease may be at its most severe. Moreover,
the effect of combining tiotropium with budeso-
nide⁄formoterol has yet to be directly assessed. These
will be addressed by the CLIMB study.
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